Entera Bio Ltd
0.0 %
183.2 %
Yet to be announced
Company Overview
Entera Bio Ltd. is a biotechnology company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need. The company's lead product candidates include EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. The company utilizes its proprietary technology platform to develop oral formulations of biologics that are currently only available via injection.
Revenue Sources
Based on the financial data and SEC filings review, Entera Bio's revenue comes from research collaborations and licensing agreements in the biotechnology sector. The company's primary focus is on developing treatments for bone and endocrine disorders. There is no evidence of revenue from prohibited sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $42,000 | $3.06m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $57,000 | $2.22m | - | - | 0.00% | 0.00% |
The company is still in its pre-commercial phase, primarily focused on research and development of its drug candidates. The financial data shows zero interest income and zero interest expense over the past four quarters. Since the company is pre-revenue and still in R&D mode, we skip the interest ratio calculations as they would not reflect the company's mature business model.
Operational Ethics
The company was founded and maintains research and development operations in Jerusalem, Israel. The company continues to operate its R&D facility in Israel, making this a material and ongoing association with the state of Israel.
Login to join the discussion